Obermatt
See Similar Stocks →

Oculis Holding

NMQ:OCS · CH1242303498
PharmaceuticalsSmall

360

18
Medium confidence — indicative
Profit price68
Owner Earnings Yield1
Dividend Yield1
Price/Sales3
Price/Book27
Return on Capital17
Cash Return on Capital15
Return on Equity11
Profit margins6
Accruals43
Owner Earnings Margin1
Sales growth6
Profit growth6
Reinvestment15
Price momentum8
Debt load91
Refinancing4
Debt Payback1
Liquidity10
Analyst ratings78
Opinion Changes88
Price Target Upside96
Market mood81
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Oculis Holding clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySwitzerland
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2022
Employees67
Websiteoculis.com
ISINCH1242303498
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
GeneticsDiabetesNeurologyOphthalmologyCentral Nervous SystemInflammationPain ManagementBiotechnologyHealth CarePharmaceutical

Description

Oculis Holding AG operates as a clinical-stage biopharmaceutical company. The company operates in Switzerland, the U.S.A, and Iceland. It has substantial expertise in therapeutics for the treatment of neuro-ophthalmic and ophthalmic diseases. The co…

Analysis

Weak and unloved

Oculis Holding AG scores below average on quality and is priced accordingly, a low-conviction position in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is adequate. The company scores 8/20 on our value-creation score: creating some value. Analysts lean positive.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
18
2026

All-time high

18

Jun 2026

All-time low

13

Mar 2026

Average rank

16

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
3
—
—
—
Price/Earnings
85
—
—
—
Price/Book
27
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
27
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Oculis Holding with its peers
Immunovant
NSQ:IMVT
86
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Genmab
CPH:GMAB
40
CountryDenmark
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Sol-Gel Technologies
NAQ:SLGL
36
CountryIsrael
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Roche
VTX:ROG
84
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Novartis
VTX:NOVN
38
CountrySwitzerland
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →
Bayer
GER:BAYN
15
CountryGermany
IndustryPharmaceuticals
SizeXX-Large
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →